A Look at the Future of Age-Related Macular Degeneration (AMD) Treatment

	Tweet

Two particularly notable research presentations at the American Academy of Ophthalmology’s Annual Meeting described new approaches to the treatment of “wet” Age-Related Macular Degeneration (AMD), the most common cause of severe vision loss in the western world in people over age 50.

“Wet” AMD is responsible for the majority of AMD-related vision loss. It is characterized by the abnormal growth of blood vessels under the retina (a sensitive area at the back of the eye).

New treatments, that act on “wet” AMD’s abnormal blood vessel growth, such as Avastin and Lucentis, have allowed some patients to obtain meaningful and sustained improvements in vision. This type of medication, termed “anti-VEGF”, is sometimes combined with a laser treatment called photodynamic therapy (PDT).

In the United States pharmacotherapies are the most common treatment approach. In the US and internationally, surgical treatment may be used when a patient’s “wet” AMD has advanced beyond the point where pharmacotherapies are useful or in situations where they are unavailable.

Milam A Brantley, Jr., MD, PhD, an assistant professor of ophthalmology and visual sciences at Washington University School of Medicine, spoke on how genetic factors may affect the success of Avastin (bevacizumab) treatment; and Zhizhong Ma, MD, described an innovative, intriguing surgical technique for “wet” AMD developed in Peking University Eye Center, Beijing, China, where she is a professor of ophthalmology and deputy director.

Dr. Brantley’s study is the first to link genetic factors to patients’ response to Avastin treatment for “wet” AMD. Previous studies had found variants in two genes, CFH and LOC387715, to be associated with AMD. Dr. Brantley’s study looked at 86 patients to see whether having either of these genetic variants affected their responses to Avastin.

“We found that patients with two copies of the CFH variant faired significantly worse than the others in response to treatment with Avastin,” Dr. Brantley said, “but we saw no differences in treatment response with the LOC387715 variant. We hope that our study and future, similar research might lead to the development of more individualized AMD treatments that will be more effective and economical.”

Adjusting patients’ treatments based on genetic tests is also underway or in development in other areas of medicine, such breast cancer.

New surgical approaches to “wet” AMD are being explored by ophthalmologists around the world. The technique developed by Dr. Ma’s group advanced the ability to sustain transplant tissue integrity and reduced complications during or after surgery, and vision improved in a majority of patients. This could make a significant difference in AMD treatment in certain population groups.

About the American Academy of Ophthalmology
AAO is the world’s largest association of eye physicians and surgeons—Eye M.D.s—with more than 27,000 members worldwide. Eye health care is provided by the three “O’s” – opticians, optometrists and ophthalmologists. It is the ophthalmologist, or Eye M.D., who can treat it all: eye diseases and injuries, and perform eye surgery.

Source: American Academy of Ophthalmology (AAO)

RELATED STORIES:
Team led by Scripps Scientists increases understanding of two types of blindness   Severe complications from cataract surgery decline   Statins may slightly raise aging eye disease risk   Gene linked to aggressive ‘wet’ age-related macular degeneration   Experts Examine Causes, Treatment and Prevention of Glaucoma   Infection tied to recalled contact lens solution   Dietary fish oils may lower risk of eye disease   Treating children’s eye infections without surgery   When Vision Dims, Some Tools Can Help Maintain Independence   New therapies expected to help reduce future visual burden of age-related eye disease   Does cataract surgery make eye disease worse?   Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]